Diagnosis and Treatment of Immune-Mediated Kidney Diseases

In this upcoming program, renal experts will discuss management of immune-mediated kidney diseases. They will discuss challenges in diagnosis of immunoglobulin A neuropathy (IgAN) and C3 glomerulopathy (C3G) and emerging treatment options for them.

Related Videos
Related Content

Akebia Continues FDA Appeal for Vadadustat as CKD Anemia Treatment

February 21st 2023

Making Sense of Hepatitis C Management in Chronic Kidney Disease

February 8th 2023

Daprodustat Receives FDA Approval for Anemia Caused by CKD on Dialysis

February 1st 2023

KDIGO Updates Clinical Practice Guideline for Diabetes Management in CKD

January 16th 2023

Traditional Risk Factors for Incident CKD Yielded Greater Racial Disparities

January 10th 2023

Akebia Continues FDA Appeal for Vadadustat as CKD Anemia Treatment

February 21st 2023

Making Sense of Hepatitis C Management in Chronic Kidney Disease

February 8th 2023

Daprodustat Receives FDA Approval for Anemia Caused by CKD on Dialysis

February 1st 2023

KDIGO Updates Clinical Practice Guideline for Diabetes Management in CKD

January 16th 2023

Traditional Risk Factors for Incident CKD Yielded Greater Racial Disparities

January 10th 2023

Akebia Continues FDA Appeal for Vadadustat as CKD Anemia Treatment

February 21st 2023

Making Sense of Hepatitis C Management in Chronic Kidney Disease

February 8th 2023

Daprodustat Receives FDA Approval for Anemia Caused by CKD on Dialysis

February 1st 2023

KDIGO Updates Clinical Practice Guideline for Diabetes Management in CKD

January 16th 2023

Traditional Risk Factors for Incident CKD Yielded Greater Racial Disparities

January 10th 2023
© 2023 MJH Life Sciences

All rights reserved.